I’d snap up this growth stock at 29p without hesitation!

This writer shines a light on one growth stock in the small-cap space whose price has nearly doubled in the past year but still looks good value.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I believe there are excellent opportunities in small-cap growth stocks today, particularly with multiple interest rate cuts on the horizon. One such opportunity is hVIVO (LSE: HVO), which provided a bullish H1 trading update yesterday (17 July)

In response, the stock rose 5% to 29p, but I reckon it’s set for further gains in the years ahead.

Created with Highcharts 11.4.3hVIVO Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Record revenue growth

AIM-listed hVIVO is a specialist contract research organisation (CRO) and world leader in testing infectious disease products using human challenge clinical trials. These are where healthy volunteers are infected with pathogens to test diseases and potential treatments. This approach can save time and money for its customers (pharmaceutical firms) when conducting trials.

Should you invest £1,000 in Aviva right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aviva made the list?

See the 6 stocks

The company recruits volunteers through its own FluCamp platform then runs the trials at its designated quarantine facilities. It also offers standalone laboratory support and clinical consultancy services.

In the six months to the end of June, the firm’s revenue jumped 30.6% year on year to a record £35.6m. Its EBITDA profit margin improved from 19.1% in H1 2023 to approximately 24%. This was driven by enhanced operational efficiencies from running multiple quarantine facilities.

Meanwhile, its cash position increased to £37.1m from £31.3m the year before. The company has no debt.

For the full year, it reaffirmed revenue guidance of £62m (10.7% growth) and said EBITDA margins were anticipated to be at the upper end of market expectations.

We have full visibility over our expected 2024 revenues and continue to deliver on our sustainable growth strategy. The orderbook remains strong in spite of record revenue delivery in H1 2024. The recent Omicron characterisation study contract and the award of our largest field study to date are two key sales highlights for H1 2024. In addition, the current sales pipeline includes several advanced stage opportunities that we expect to convert in the coming months. 

Yamin ‘Mo’ Khan, CEO of hVIVO, H1 2024 trading update

Risk and competition

One risk here is that human challenge studies are subject to stringent regulations. Any changes in such requirements or non-compliance could lead to delays, increased costs, or the halting of studies.

Plus, there are other firms around the world that compete with hVIVO in attracting contracts for clinical trials related to infectious diseases and respiratory illnesses. So it isn’t the only show in town.

New state-of-the-art facility

Despite these risks, things look very bright here. The company has just opened the world’s largest human challenge trial unit in London’s Canary Wharf. This will enable hVIVO to broaden its offerings to include new pathogen models and other services.

This new facility is expected to provide the capacity for £100m in revenue by 2028. With an assumed EBITDA margin of 24%, this gives a price-to-EBITDA ratio of around 8.5 for 2028. That’s attractive, assuming everything goes to plan, which isn’t guaranteed but looks increasingly likely.

For this year, the stock is trading on a forward price-to-earnings (P/E) multiple of 21. Again, I think that’s decent value for a fast-growing firm.

Finally, the stock is still 22% lower than a high of 38p reached back in 2021. I wouldn’t be surprised to see this one go on to hit new highs. If I didn’t already own the stock, I’d add it to my portfolio at 29p right now.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »